series-c-plus
Stage
2014
Founded
2
Investors
About
Eloxx Pharmaceuticals develops small molecule genetic therapies targeting nonsense mutations for rare genetic diseases such as Alport Syndrome, using proprietary platform technologies including TURBO-ZM™ and Ribosome Modulating Agents.
Explore Eloxx Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.